rs2542052 — APOC3

Promoter variant that reduces APOC3 expression, associated with lower triglycerides, favorable lipoprotein profiles, and enrichment in centenarians

See your personal result for APOC3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APOC3 -641A>C — The Longevity Promoter Variant

Apolipoprotein C-III (APOC3) is one of the most potent brakes in the human triglyceride clearance system. The liver secretes this small 79-amino-acid protein onto triglyceride-rich lipoproteins11 triglyceride-rich lipoproteins
VLDL and chylomicrons, the particles that carry fat through the bloodstream, where it inhibits lipoprotein lipase22 lipoprotein lipase
the enzyme anchored to blood vessel walls that breaks down circulating triglycerides. The more APOC3 you produce, the slower your body clears fat from the bloodstream. The rs2542052 variant in the APOC3 promoter sits at position -641 relative to the transcription start site — a region that controls how much of this protein the liver makes.

The C allele at this position reduces APOC3 transcription. Individuals homozygous for this allele produce approximately 30% less APOC3 than those carrying the common A allele, resulting in more efficient triglyceride clearance, smaller and denser VLDL particles, larger LDL particle sizes, and higher HDL cholesterol levels. These are precisely the lipoprotein characteristics associated with reduced cardiovascular and metabolic disease.

The Mechanism

The APOC3 promoter contains several regulatory elements, including an insulin-responsive element33 insulin-responsive element
a DNA sequence that normally allows insulin to suppress APOC3 transcription after meals, reducing APOC3 production when glucose is high. rs2542052 falls within a cluster of four promoter SNPs (rs2542052, rs10892037, rs11568823, rs2854116) that are in complete linkage disequilibrium with each other — they almost always co-occur on the same haplotype. The -641C allele tags a haplotype associated with reduced APOC3 promoter activity.

APOC3 raises triglycerides through three coordinated mechanisms: it displaces lipoprotein lipase from lipid droplets44 displaces lipoprotein lipase from lipid droplets, blocks hepatic uptake of remnant particles55 blocks hepatic uptake of remnant particles, and promotes hepatic VLDL assembly and secretion. Lower APOC3 production from the C allele simultaneously relieves all three brakes, producing a comprehensively favorable lipid phenotype. Hepatic APOC3 expression is further induced by dietary carbohydrates (especially fructose) and saturated fat, and suppressed by insulin, PPAR-alpha activators, and omega-3 fatty acids — meaning diet and lifestyle directly modulate how much the genotype matters.

The Evidence

The landmark finding came from a 2006 PLOS Biology study by Atzmon and colleagues66 2006 PLOS Biology study by Atzmon and colleagues
Atzmon et al. "Lipoprotein Genotype and Conserved Pathway for Exceptional Longevity in Humans." PLoS Biology, 2006. Genotyping 213 Ashkenazi Jewish centenarians (mean age 98.2 years), 216 of their offspring, and 258 age-matched controls revealed that CC homozygosity was found in 25% of centenarians, 20% of their offspring, and only 10% of controls (p = 0.0001 and p = 0.001, respectively). CC homozygotes had approximately 30% lower serum APOC3 (10.1 vs 13.2 mg/dL), significantly lower triglycerides in females, lower hypertension prevalence (28.6% vs 44%, p = 0.026), greater insulin sensitivity, and a prospectively confirmed survival advantage (log-rank p = 0.0008).

These population genetics findings align with mechanistic studies in two major NEJM reports. Jørgensen et al. 201477 Jørgensen et al. 2014 followed 75,725 participants and found that individuals carrying loss-of-function APOC3 mutations had 44% lower nonfasting triglycerides and a 41% reduced risk of ischemic vascular disease (HR 0.59). A complementary study by Crosby et al.88 study by Crosby et al. confirmed a 40% lower coronary heart disease risk in APOC3 loss-of-function carriers. While rs2542052 is a common regulatory variant rather than a loss-of-function mutation, it works through the same pathway of reduced APOC3 expression — and the centenarian data suggest lifelong partial reductions in APOC3 confer meaningful longevity advantages.

The longevity association in Ashkenazi centenarians was specific to rs2542052 (and its linked haplotype), not to the other classic APOC3 variants (rs2854117, rs2854116, rs4520, rs5128, rs4225), which showed no association with triglyceride levels, insulin sensitivity, or blood pressure in the same population. This specificity supports a causal role for the -641 promoter region rather than a broader LD sweep.

Practical Actions

The C allele reduces APOC3 production — but diet determines whether this advantage is realized. Hepatic APOC3 expression is powerfully induced by saturated fat, refined carbohydrates, and fructose. Even CC homozygotes can develop elevated triglycerides with a diet high in these inducers. Conversely, omega-3 fatty acids (EPA and DHA) suppress APOC3 expression through PPAR-alpha activation, lowering ApoC-III concentrations. For AA and AC individuals, omega-3s provide a dietary mechanism to partially compensate for the genetically higher APOC3 set point.

Monitoring fasting triglycerides is especially relevant for AA homozygotes, who lack the promoter-reducing C allele and produce the most APOC3. A fasting triglyceride level above 150 mg/dL warrants dietary intervention; above 500 mg/dL increases acute pancreatitis risk. Fibrate medications (fenofibrate, gemfibrozil) work partly by activating PPAR-alpha, which reduces APOC3 expression — making them mechanistically targeted for A allele carriers with persistently elevated triglycerides.

Interactions

rs2542052 is in complete LD with rs2854116 (T-455C) and rs10892037, forming a promoter haplotype block. The closely related rs5128 variant in the APOC3 3'UTR influences APOC3 translation through a different mechanism (microRNA binding) and may compound effects when co-inherited.

APOC3 sits in the apolipoprotein gene cluster (APOA1-APOC3-APOA4-APOA5) on chromosome 11q2399 apolipoprotein gene cluster (APOA1-APOC3-APOA4-APOA5) on chromosome 11q23
this cluster plays coordinated roles in triglyceride metabolism. Variants in APOA5 (rs662799, rs3135506) also powerfully raise triglycerides. Carrying A alleles at both rs2542052 (higher APOC3 expression) and risk alleles at rs662799 (lower APOA5 expression) would compound triglyceride burden and amplify the dietary importance of omega-3s and carbohydrate restriction.

Insulin strongly suppresses APOC3 transcription in the liver. Insulin resistance, metabolic syndrome, and type 2 diabetes therefore tend to elevate APOC3 even in individuals without risk genotypes. For AA homozygotes with any degree of insulin resistance, the combined effect on APOC3 production and triglyceride accumulation is especially pronounced.

Nutrient Interactions

omega-3 fatty acids increased_need
saturated fat increased_sensitivity

Genotype Interpretations

What each possible genotype means for this variant.

CC Longevity Allele Homozygote Beneficial

Reduced APOC3 expression and favorable lipoprotein profile

The study by Atzmon et al. (PLOS Biology, 2006) found CC homozygosity in 25% of centenarians (mean age 98.2 years) versus 10% of age-matched controls (p = 0.0001), and in 20% of centenarian offspring (p = 0.001) — suggesting this advantage is heritable and persists through middle age. Mean APOC3 levels were 10.1 mg/dL in CC individuals compared to 13.2 mg/dL in CA/AA carriers (p < 0.05), and hypertension prevalence was 28.6% versus 44% (p = 0.026). Kaplan-Meier survival analysis confirmed a prospective survival advantage (log-rank p = 0.0008).

This beneficial genotype mirrors, in a partial and common way, what rare loss-of-function mutations in APOC3 do dramatically: carriers of those rare mutations have 44% lower triglycerides and 41% lower ischemic vascular disease risk. Your CC genotype achieves a meaningful fraction of this biological advantage through reduced promoter activity rather than protein abolition.

This advantage is diet-sensitive: even CC individuals can elevate APOC3 with diets high in saturated fat, fructose, and refined carbohydrates, which induce hepatic APOC3 expression regardless of genotype. The advantage is most apparent with a diet that does not override the genetic predisposition toward lower APOC3 production.

AC Intermediate Expression Intermediate

One copy of the longevity-associated C allele — partial reduction in APOC3

The codominant pattern means AC heterozygotes have intermediate APOC3 levels, intermediate triglyceride clearance efficiency, and intermediate lipoprotein profiles compared to the two homozygous states. While the landmark longevity data focused on CC versus AA/AC combined, the dose-response biology of APOC3 suggests one C allele provides partial but real advantage in lipid metabolism relative to having no C alleles.

Diet remains the primary modifiable lever. Saturated fat and fructose induce hepatic APOC3 expression; omega-3 fatty acids and PPAR-alpha activators suppress it. With one A allele contributing to baseline APOC3 production, dietary factors have outsized impact on your actual triglyceride levels. Omega-3 fatty acid supplementation is particularly effective at partially compensating by suppressing APOC3 transcription via PPAR-alpha.

AA High Expression Reduced

Higher baseline APOC3 production — least favorable lipoprotein clearance

The centenarian study found mean serum APOC3 of 13.2 mg/dL in AA/AC carriers versus 10.1 mg/dL in CC homozygotes — about 30% higher. Higher APOC3 levels inhibit lipoprotein lipase more strongly, resulting in slower clearance of VLDL triglycerides, longer-lasting postprandial lipemia (elevated blood fat after meals), and a tendency toward smaller, denser LDL particles. The hypertension prevalence difference (44% in AA/AC vs 28.6% in CC, p = 0.026) suggests the effect extends beyond lipids to broader cardiometabolic outcomes.

The biological insight from rare APOC3 loss-of-function mutations — where complete protein abolition reduces cardiovascular risk by 40-41% — contextualizes what lifelong higher APOC3 expression means over decades. While AA is the common genotype and the absence of the C allele is not equivalent to a pathogenic mutation, the dose-response relationship between APOC3 expression and cardiometabolic outcomes is well-established.

The good news is that dietary and supplemental interventions can meaningfully suppress APOC3 expression: omega-3 fatty acids, PPAR-alpha activating interventions (fibrates act through this mechanism), and reduction of saturated fat and refined carbohydrate inducers all lower APOC3 at the transcriptional level — offering a direct genetic compensation pathway.